Prostate Ca
57 programs · 56 companies
Programs
57
Companies
56
Trials
55
MOAs
37
STINGagSOS1iCD47iCl18.2KIF18AiBiTEAHRantSHP2iCGRPantCDK4/6i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Preclinical | RET | ||
| MRK-1380 | Preclinical | SHP2 | ||
| AZN-6294 | Phase 2/3 | APOC3 | ||
| Zorivorutinib | Approved | DLL3 | ||
| TAK-1836 | Preclinical | EGFR | ||
| BII-8315 | NDA/BLA | CDK2 | ||
| BII-5449 | Phase 3 | FXIa | ||
| Daratuximab | Phase 1 | PRMT5 | ||
| INC-2432 | Phase 2 | CD47 | ||
| ION-8812 | Phase 1 | MALT1 | ||
| MDG-4513 | Phase 1/2 | CD3 | ||
| VKT-6548 | Phase 2/3 | PD-L1 | ||
| Pemitinib | Preclinical | BTK | ||
| Sovacagene | Phase 1/2 | Menin | ||
| SDG-1247 | Phase 1 | CD19 | ||
| Zenocagene | Approved | IL-23 | ||
| Fixaderotide | Phase 2 | CFTR | ||
| HOV-IIT-732 | Phase 3 | FcRn | ||
| Zenotuximab | Phase 1/2 | PI3Kα | ||
| PCL-2819 | Preclinical | SMN2 | ||
| Rimacilimab | Phase 2/3 | MDM2 | ||
| Polalemzoparlimab | Phase 3 | SMN2 | ||
| ELO-2344 | Phase 3 | PI3Kα | ||
| RLY-4615 | Phase 3 | PD-1 | ||
| Tezesotorasib | Phase 2/3 | DLL3 | ||
| CAN-3547 | NDA/BLA | FcRn | ||
| NUW-6701 | Approved | TROP-2 | ||
| Datonesiran | NDA/BLA | PD-1 | ||
| Pemiratamab | Phase 2 | ALK | ||
| Zorirelsin | Phase 3 | CDK2 | ||
| OCT-7288 | Phase 2/3 | CD123 | ||
| CHR-2685 | Phase 2 | SGLT2 | ||
| AMB-4811 | Preclinical | ALK | ||
| NER-1837 | Phase 1/2 | KRASG12C | ||
| Bemaglumide | Phase 3 | MDM2 | ||
| Miriderotide | Phase 1/2 | GPRC5D | ||
| FRE-IIT-649 | Phase 3 | MET | ||
| SOR-1685 | Phase 2 | PSMA | ||
| 006-348 | Phase 1/2 | CD38 | ||
| Daracilimab | Phase 2 | CD38 | ||
| Polazasiran | Preclinical | TNFα | ||
| Mavutenlimab | Phase 2 | EGFR | ||
| Pemiinavolisib | Phase 1/2 | WRN | ||
| MIR-1203 | Phase 1 | PD-1 | ||
| Rimavorutinib | Phase 3 | PARP | ||
| ABD-5382 | Preclinical | CD38 | ||
| AII-IIT-890 | Approved | PD-L1 | ||
| HOS-IIT-510 | Preclinical | SOS1 | ||
| 600-3422 | Phase 1 | KRASG12D | ||
| SCI-9998 | Approved | USP1 | ||
| CYB-1519 | Phase 2/3 | GLP-1R | ||
| Fixatuximab | Approved | CDK2 | ||
| WST-9696 | Phase 3 | PCSK9 | ||
| Nidarelsin | Phase 2/3 | C5 | ||
| Fixatenlimab | NDA/BLA | MALT1 | ||
| MED-9563 | Approved | GLP-1R | ||
| VEE-9538 | Phase 1 | HER2 |
Trials (55)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT06590940 | RHH-5389 | Preclinical | Not yet recr... |
| NCT04412401 | MRK-1380 | Preclinical | Completed |
| NCT08172774 | MRK-1380 | Preclinical | Completed |
| NCT05160918 | Zorivorutinib | Approved | Terminated |
| NCT04555539 | Zorivorutinib | Approved | Terminated |
| NCT06739179 | TAK-1836 | Preclinical | Active |
| NCT07387513 | TAK-1836 | Preclinical | Recruiting |
| NCT06055330 | BII-8315 | NDA/BLA | Active |
| NCT07135024 | BII-5449 | Phase 3 | Completed |
| NCT03626571 | Daratuximab | Phase 1 | Not yet recr... |
| NCT06393201 | INC-2432 | Phase 2 | Active |
| NCT06865309 | ION-8812 | Phase 1 | Active |
| NCT03887663 | VKT-6548 | Phase 2/3 | Recruiting |
| NCT06945438 | SDG-1247 | Phase 1 | Terminated |
| NCT08880835 | Zenocagene | Approved | Recruiting |
| NCT06169993 | HOV-IIT-732 | Phase 3 | Active |
| NCT07019332 | PCL-2819 | Preclinical | Active |
| NCT06002684 | Polalemzoparlimab | Phase 3 | Recruiting |
| NCT08832268 | ELO-2344 | Phase 3 | Completed |
| NCT08890452 | ELO-2344 | Phase 3 | Not yet recr... |